Skip to main content
SpringerLink
Log in

Management Strategies for Diabetes

  • Chapter
  • First Online:
Managing Diabetes

  • 1612 Accesses

Abstract

Diabetes remains one of the biggest health challenges in the developed world, with a current prevalence of approximately 4 % of the UK general population. In addition, there is an unprecedented rise in the incidence of type 2 diabetes in recent times along with a much earlier age of onset. At the same time, the advent of newer drugs, especially those involving the incretin axis, makes choosing therapeutics a challenging task.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2009;87:4–14.

    Google Scholar 

  2. Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med. 1993;329:978–986.

    Google Scholar 

  3. Reichard P, Nilsson B-Y, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329:304–309.

    Google Scholar 

  4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.

    Google Scholar 

  5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865.

    Google Scholar 

  6. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–117.

    Google Scholar 

  7. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577–1596.

    Google Scholar 

  8. National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes (Clinical guideline 87). 2009. www.nice.org.uk/CG87. Accessed September 5, 2012.

  9. Weng JP, Li YB, Xu W, et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomized parallel-group trial. Lancet. 2008;371:1753–1760.

    Google Scholar 

  10. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care. 1997;20:1353–1356.

    Google Scholar 

  11. Weng JP, Li YB, Xu W, et al. The effect of short-term continuous subcutaneous insulin infusion treatment on beta-cell function in newly diagnosed type 2 diabetic patients. Chin J Diabetes (Chin). 2003;11:10–15.

    Google Scholar 

  12. Zhu F, Ji LN, Han XY, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Chin J Diabetes (Chin). 2003;11:5–9.

    Google Scholar 

  13. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004;27:1028–1032.

    Google Scholar 

  14. Li YB, Xu W, Liao ZH, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function. Diabetes Care. 2004; 27:2597–2602.

    Google Scholar 

  15. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:260–272.

    Google Scholar 

  16. Duckworth W, Abraira C, Mortiz T, et al; for the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139.

    Google Scholar 

  17. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559.

    Google Scholar 

  18. Department of Health. National Service Framework for Diabetes: Delivery Strategy; 2003.

    Google Scholar 

  19. Nicolucci A, Cavaliere D, Scorpiglione N, et al, A comprehensive assessment of the avoidability of long-term complications of diabetes, Diabetes Care. 1996;19:927–933.

    Google Scholar 

  20. Healthcare Commission. Managing diabetes: improving services for people with diabetes. www.cqc.org.uk/publications.cfm?fde_id=559. Accessed September 5, 2012.

  21. Santaguida PL, Balion C, Hunt D, et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Summary, Evidence Report/Technology Assessment No. 128; 2005. www.ahrq.gov/downloads/pub/evidence/pdf/impglucose/impglucose.pdf. Accessed September 5, 2012.

  22. US Department of Health and Human Services. National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988–1994 (CD -ROM ). Public Use Data File Documentation Number 76200. Hyattsville, MD: Centers for Disease Control and Prevention;1996.

    Google Scholar 

  23. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350.

    Google Scholar 

  24. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention in type 2 diabetes. Diabetes Care. 1999;22:623–634.

    Google Scholar 

  25. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865.

    Google Scholar 

  26. Turner RC, Cull CA, Frighi V, Holman RR; for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies. JAMA. 1999;281:2005–2012.

    Google Scholar 

  27. Bolen S, Wilson L, Vassy J, et al. Comparative effectiveness and safety of oral diabetes medications for adults with type 2 diabetes. Comparative effectiveness review No. 8. Rockville, MD: Agency for Healthcare Research and Quality; 2007. www.effectivehealthcare.ahrq.gov/ repFiles/OralFullReport.pdf. Accessed September 5, 2012.

  28. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus Statement of the America Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203.

    Google Scholar 

  29. US Food and Drug Administration. “FDA Drug Safety Communication: Avandia (rosiglitazone) labels now contain updated information about cardiovascular risks and use in certain patients.” FDA website. www.fda.gov/Drugs/DrugSafety/ucm241411.htm. Accessed September 5, 2012.

  30. Medicines and Healthcare products Regulatory Agency. “Europe-wide suspension of marketing authorisation for Avandia, Avandamet and Avaglim (rosiglitazone).” MHRA website. www.mhra.gov.uk/NewsCentre/Pressreleases/CON 094127. Accessed September 5, 2012.

  31. Department of Health. Annex A: Quality indicators - Summary of points. DHA website. www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/ dh_120152.pdf. Accessed September 5, 2012.

Download references

Author information

Authors and Affiliations

  1. Royal Liverpool and Broadgreen University Hospital, Liverpool, UK

    Rupa Ahluwalia

Authors
  1. Rupa Ahluwalia
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. General Medicine/Diabetes/Endocrinology, Royal Liverpool University Hospital, Liverpool, United Kingdom

    Jiten Vora

  2. Department of General Medicine, Llandough Hospital, Penarth, United Kingdom

    Marc Evans

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Healthcare

About this chapter

Cite this chapter

Ahluwalia, R. (2012). Management Strategies for Diabetes. In: Vora, J., Evans, M. (eds) Managing Diabetes. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-908517-81-4_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-908517-81-4_2

  • Published:

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-908517-57-9

  • Online ISBN: 978-1-908517-81-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation